SCHEMBL20393935

SCHEMBL20393935

CN(C1CCCCC1)S(=O)(=O)c1ccc(S(=O)(=O)N(Cc2ccc(F)cc2)C2CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ ALDH1A1 P00352 5/20 0.66
▸ USP2 O75604 1/20 0.66
▸ HDAC3 O15379 1/20 0.60
▸ HDAC8 Q9BY41 1/20 0.60
▸ HDAC6 Q9UBN7 1/20 0.60
▸ CNR1 P21554 4/20 0.57
▸ CNR2 P34972 4/20 0.57
▸ PSEN1 P49768 3/20 0.55
▸ PSEN2 P49810 3/20 0.55
▸ APH1B Q8WW43 3/20 0.55
▸ NCSTN Q92542 3/20 0.55
▸ APH1A Q96BI3 3/20 0.55
▸ PSENEN Q9NZ42 3/20 0.55
▸ HTR2A P28223 1/20 0.54
▸ HTR2C P28335 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.53
▸ MAPT P10636 3/20 0.51
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20847632 0.87 HDAC8 (0.74) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL20393932 0.85 KMT2A (0.69) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL20387947 0.83 KMT2A (0.67) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL14842380 0.82 MEN1 (1.00) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL14842844 0.81 MEN1 (0.76) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL20839243 0.80 HDAC8 (0.65) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL22388774 0.78 MEN1 (0.62) MEN1KMT2AALDH1A1USP2HDAC3
SCHEMBL12188831 0.77 HTR2A (0.72) MEN1KMT2AALDH1A1USP2HTR2A
SCHEMBL20393944 0.77 ALDH1A1 (1.00) MEN1KMT2AALDH1A1USP2CNR1
SCHEMBL20847582 0.77 HDAC6 (0.62) MEN1KMT2AALDH1A1USP2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10913710-B2 Benzene disulfonamide for the treatment of cancer MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) 2021-02-09 — — US disclosed
US-10913710-B2 Benzene disulfonamide for the treatment of cancer MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE) 2021-02-09 — — US disclosed
EP-3351544-A1 BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2018-07-25 — — EP disclosed
EP-3351544-A1 BENZENE DISULFONAMIDE FOR THE TREATMENT OF CANCER Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2018-07-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913710-B2 Benzene disulfonamide for the treatment of cancer DUSP6, DUSP26, RASSF2 MEN1 3103/4885KMT2A 4498/4885ALDH1A1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback